FDA Advises Against Use of BioZorb Markers and BioZorb LP Markers
The FDA has announced that BioZorb Markers and BioZorb LP Markers should no longer be used.
Related Articles
Mechanistic and kinetic insights into transcription factor biology via acute protein depletion
Genetic loss-of-function studies have facilitated the characterization of hematopoietic transcription factors (TFs) in both normal physiology and pathological conditions. The knockout or knockdown of a…
JAK Inhibitors Remain the Gold Standard in Myelofibrosis
Daniel DeAngelo MD, PhD, discusses the incorporation of JAK inhibitors into the myelofibrosis treatment paradigm.
Navigating Adverse Effects of JAK Inhibitors in Myeloproliferative Neoplasms
Prithviraj Bose, MD, discusses the most critical adverse effects seen with each of the 4 approved JAK inhibitors for the treatment of myeloproliferative neoplasms.
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC
DE397 is the first MAT2A inhibitor to show clinical activity and safety in patients with MTAP-deletion urothelial cancer and non–small cell lung cancer.
FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Ph+ Chronic-Phase Chronic Myeloid Leukemia
The FDA has granted accelerated approval to asciminib for newly diagnosed, Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.
IASLC Academy | IASLC
The IASLC Academy is a prestigious program geared toward early-career physicians worldwide who aspire to pursue academic careers in thoracic oncology.
Interpreting IDeate-Lung02 Trial Outcomes
Joshua K. Sabari, MD, discusses the efficacy outcomes from the Ideate-Lung02 trial, noting the 52.4% ORR, 5.9-month median DOR, and 12.2-month OS and emphasizing that…
Short-term sensorimotor training incorporating cognitive tasks for pediatric survivors of posterior fossa tumors: a pilot study
Journal of Neuro-Oncology – Posterior fossa tumors account for half of all childhood brain tumors, prompting the search for effective and affordable interventions to combat…
Letter Warns Clinicians of Severe Infections With Pralsetinib for NSCLC
An ad-hoc analysis found a higher rate of severe and life-threatening infections in patients with RET-mutant lung cancer treated with pralsetinib.
